enGene (NASDAQ:ENGN) Upgraded to “Hold” at Wall Street Zen

enGene (NASDAQ:ENGN) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

ENGN has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of enGene in a report on Monday, March 9th. Guggenheim reaffirmed a “buy” rating on shares of enGene in a research note on Tuesday. Raymond James Financial reissued a “strong-buy” rating and issued a $27.00 target price on shares of enGene in a research note on Monday. Citigroup restated a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Finally, Oppenheimer lowered their price target on shares of enGene from $33.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.86.

enGene Stock Down 1.9%

ENGN stock opened at $7.16 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 6.30. The company’s 50 day simple moving average is $9.39 and its 200-day simple moving average is $8.12. enGene has a 12 month low of $2.65 and a 12 month high of $12.25. The firm has a market capitalization of $479.65 million, a PE ratio of -3.18 and a beta of -0.29.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.11. Equities analysts expect that enGene will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On enGene

Several large investors have recently added to or reduced their stakes in ENGN. Cresset Asset Management LLC purchased a new stake in enGene in the second quarter valued at approximately $36,000. Paloma Partners Management Co purchased a new position in shares of enGene in the 2nd quarter worth $38,000. PFS Partners LLC acquired a new position in enGene in the third quarter valued at $61,000. Raymond James Financial Inc. boosted its holdings in enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after acquiring an additional 7,932 shares during the last quarter. Finally, Hudson Bay Capital Management LP purchased a new stake in enGene during the third quarter valued at about $76,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

Key enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Strong clinical progress for lead candidate detalimogene voraplasmid — a 63% complete response rate at 3 months in NMIBC, favorable tolerability, and pivotal cohort enrollment above targets. Management plans a LEGEND cohort update at a spring medical conference and expects a BLA submission in H2 2026, which are clear binary catalysts that could drive the stock if results and the regulatory pathway remain favorable. enGene Holdings: Key Catalysts Incoming For 2026
• Positive Sentiment: HC Wainwright raised EPS forecasts across multiple 2026–2029 periods and reiterated a “Buy” rating with a $25 price target — the analyst cut loss expectations (improved EPS) for FY2026–2029 and lifted near‑term quarter forecasts, signaling improved underlying assumptions about development progress and cash runway that can support a higher valuation if milestones are met. MarketBeat: HC Wainwright raises estimates for enGene
• Neutral Sentiment: Industry/sector noise unrelated to enGene — coverage about automakers phasing out V6 engines is not relevant to ENGN’s biotech story and is unlikely to affect the stock’s near-term performance. Why Automakers Are Phasing Out V6 Engines
• Negative Sentiment: Valuation and execution risk remain — consensus still anticipates continued losses (negative EPS), the company must deliver confirmatory pivotal data and a successful BLA, and the stock is trading below its 50‑day moving average, leaving downside if upcoming updates disappoint or timelines slip. enGene profile and metrics

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.